切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2020, Vol. 09 ›› Issue (03) : 292 -295. doi: 10.3877/cma.j.issn.2095-3224.2020.03.015

所属专题: 文献

综述

BRAF V600E基因突变在结直肠癌治疗中的研究进展
张祥涛1, 刘睿清1, 张宪祥1,(), 卢云1,()   
  1. 1. 266000 青岛大学附属医院黄岛院区胃肠外二科
  • 收稿日期:2019-11-16 出版日期:2020-06-25
  • 通信作者: 张宪祥, 卢云
  • 基金资助:
    国家自然科学基金青年基金(No.81802473)

Advances in the study of BRAF V600E mutation in the treatment of colorectal cancer

Xiangtao Zhang1, Ruiqing Liu1, Xianxiang Zhang1,(), Yun Lu1,()   

  1. 1. Second Gastrointestinal Department, Huangdao Hospital, Affiliated Hospital of Qingdao University, Qingdao 266000, China
  • Received:2019-11-16 Published:2020-06-25
  • Corresponding author: Xianxiang Zhang, Yun Lu
  • About author:
    Corresponding authors: Lu Yun, Email:
    Zhang Xianxiang, Email:
引用本文:

张祥涛, 刘睿清, 张宪祥, 卢云. BRAF V600E基因突变在结直肠癌治疗中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2020, 09(03): 292-295.

Xiangtao Zhang, Ruiqing Liu, Xianxiang Zhang, Yun Lu. Advances in the study of BRAF V600E mutation in the treatment of colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(03): 292-295.

结直肠癌是第三大常见癌症,在全球相关癌症死亡率中排名第四。RAS-RAF-MEK-ERK(MAPK)通路的本构性激活在结直肠癌的发生发展中起着重要作用。V-raf鼠肉瘤毒癌基因同源体B(BRAF)是MAPK信号通路上的激酶,在结直肠癌发展中起重要作用。临床观察发现,约8%~10%的结直肠癌病例中存在BRAF V600E突变,并预示较低的中位生存率,对结直肠癌的预后有预测价值。初步探讨BRAF V600E突变,为结直肠癌的分子靶向治疗提供新的思路。

Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-related deaths worldwide. Constitutive activation of Ras-Raf-Mek-Erk (MAPK) pathway plays an important role in the occurrence and development of CRC. V-raf murine sarcoma viral oncogene homolog (BRAF) is a kinase in the MAPK signaling pathway and plays an important role in the development of colorectal cancer. Clinical observations showed that BRAF V600E was found in approximately 8%~10% of CRC cases and was associated with significantly lower median overall survival. It has predictive value for the prognosis of colorectal cancer. A preliminary study on BRAF V600E mutation provides a new idea for molecular targeted therapy of colorectal cancer.

[1]
Das TM, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, 2013 [J]. Nature, 2013, 494(7436): 251-255.
[2]
Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, 2014 [J]. Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 2014, 20(7): 1965.
[3]
Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, 2010 [J]. Nature, 2010, 468(7326): 973.
[4]
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, 2012 [J]. Nature, 2012, 483(7387): 100.
[5]
Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer, 2012 [J]. Cancer Research, 2012, 72(3): 779.
[6]
Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer, 2009 [J]. Nat Rev Cancer, 2009, 9: 489-499.
[7]
Ewing I, Hurley JJ, Josephides E, et al. The molecular genetics of colorectal cancer, 2014 [J]. Frontline Wastroenterol, 2014, 5(1): 26-30.
[8]
Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis, 2014 [J]. Eur J Cancer Prev, 2014, 23(4): 246-257.
[9]
Lengauer C, Kinzler KW, Vogelstein B, et al. Genetic instability in colorectal cancers, 1997 [J]. Nature, 1997, 386: 623-627.
[10]
Gordon DJ, Resio B, Pellman D, et al. Causes and consequences of aneuploidy in cancer, 2012 [J]. Nat Rev Genet, 2012, 13: 189-203.
[11]
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, 2007 [J]. Histopathology, 2007, 50: 113-130.
[12]
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, 2006 [J]. Nat Genet, 2006, 38: 787-793.
[13]
Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors, 1998 [J]. Gut, 1998, 42: 673-679.
[14]
Walther A, Houlston R, Tomlinson I, et al. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis, 2008 [J]. Gut, 2008, 57: 941-950.
[15]
Watanabe T, Kobunai T, Yamamoto Y, et al. Chromosomal instability(CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer, 2012 [J]. J Clin Oncol, 2012, 30(18): 2256-2264.
[16]
Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients, 2006 [J]. Gastroenterology, 2006, 131: 729-737.
[17]
Popat S, Hubner R, Houlston RS, et al. Systematic review of microsatellite instability and colorectal cancer prognosis, 2005 [J]. J Clin Oncol, 2005, 23: 609-618.
[18]
Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy, 2011 [J]. J Natl Cancer Inst, 2011, 103: 863-875.
[19]
Müller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group, 2008 [J]. Int J Colorectal Dis, 2008, 23: 1033-1039.
[20]
Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, 2005 [J]. Cancer Res, 2005, 65: 6063-6069.
[21]
Ogino S, Shima K, Meyerhardt J, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, 2012 [J]. Clin Cancer Res, 2012, 18(3): 890-900.
[22]
Bond CE, Nancarrow DJ, Wockner LF, et al. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability [J]. PLoS ONE, 2014, 9(3): e91739.
[23]
Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas, 2004 [J]. Int J Cancer, 2004, 108: 237-242.
[24]
Sérgia V, Cátia M, Luís C, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis, 2008 [J]. BMC Cancer, 2008, 8: 255.
[25]
Riccio A, Aaltonen LA, Godwin AK, et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability, 1999 [J]. Nature Genetics, 1999, 23(3): 266-268.
[26]
Tricarico R, Cortellino S, Riccio A, et al. Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis, 2015 [J]. Oncotarget, 2015, 6(40): 42892.
[27]
Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer, 1999 [J]. Proc Nati Acad Sci USA, 1999, 96: 8681-8686.
[28]
孙乃恩,孙东旭,朱德煦. 分子遗传学[M]. 南京: 南京大学出版社, 2001.
[29]
O′Brien MJ. Hyperplastic and serrated polyps of the colorectum, 2007 [J]. Gastroenterol Clin North Am, 2007, 36: 947-968,viii.
[30]
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instabilityand is tightly associated with BRAF mutation in colorectal cancer, 2006 [J]. Nat Genet, 2006, 38: 787-793.
[31]
Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG islandmethylator phenotype in colon cancer, 2005 [J]. Gastroenterology, 2005, 129: 837-845.
[32]
Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer [J]. Nat Genet, 2006, 38(7): 787-793.
[33]
Kambara T, SimmsL A, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum, 2004 [J]. Gut, 2004, 53(8): 1137-1144.
[34]
Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis, 2007 [J]. Journal of Pathology, 2007, 212(2): 124-133.
[35]
Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort, 2012 [J]. European Journal of Cancer, 2012, 48(1): 94-100.
[36]
Santarpia L, Lippman SM, Elnaggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy, 2012 [J]. Expert Opinion on Therapeutic Targets, 2012, 16(1): 103-119.
[37]
Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, 2004 [J]. Cell, 2004, 116: 855-867.
[38]
Xiong J, He M, Hansen K, et al. The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma, 2016 [J]. Gynecol Oncol, 2016, 142: 163-168.
[39]
Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy, 2014 [J]. Pharmacol Ther, 2014, 142: 176-182.
[40]
Fang M, Ou J, Hutchinson L, et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype, 2014 [J]. Molecular Cell, 2014, 55(6): 904-915.
[41]
Martín Martorell P, Huerta M, Compañ Quilis A, et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients, 2017 [J]. Clin Lung Cancer, 2017, 18(6): e395-e402.
[42]
宋敏,孙亚琼,张莉,等. 结直肠癌组织KRAS和BRAF基因突变情况及意义[J]. 山东医药, 2014, (32): 32-34.
[43]
Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumabor cetuximab in metastatic colorectal cancer, 2008 [J]. J Clin Oncol, 2008, 26(35): 5705-5712.
[44]
Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma, 2010 [J]. N Engl J Med, 2010, 363(9): 809-819.
[45]
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, 2014 [J]. N Engl J Med, 2014, 371(20): 1877-1888.
[46]
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, 2005 [J]. PLoS Med, 2005, 2(3): e73.
[47]
Kopetz S, Desai J, Chan E, et al. Phase Ⅱ pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer, 2015 [J]. J Clin Oncol, 2015, 33(34): 4032-4038.
[48]
Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer [J]. J Clin Oncol, 2015, 33(34): 4023-4031.
[49]
Kopetz S, McDonough SL, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406), 2017 [J]. J Clin Oncol, 2017, 35: 520.
[50]
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in V600E-mutated colorectal cancer.N, 2015 [J]. Engl J Med, 2015,10.1056/NEJMoa1908075.
[51]
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency, 2015 [J]. JN Engl J Med, 2015, 372(26): 2509-2520.
[1] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[2] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[3] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[4] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[5] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[6] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[7] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[8] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[9] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[12] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[13] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[14] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[15] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
阅读次数
全文


摘要